Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1092-1098

  Teunissen, C E ^a   Sombekke, M ^a   Van Winsen, L ^a   Killestein, J ^a   Barkhof, F ^a   Polman, C H ^a   Dijkstra, C D ^a   Blankenstein, M A ^a   Pratico, D ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

biomarkers; clinically isolated syndrome; isoprostanes; Multiple sclerosis; oxidative stress; plasma; progression

Indexed keywords

8,12 ISO IPF2ALPHA VI; GADOLINIUM; ISOPROSTANE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; SCORING SYSTEM;

EID: 84864141989     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511433306     Document Type: Article

References (35)

1. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 2000 ; 123: 1174-1183
2. Bö L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol. 1994 ; 36: 778-786
3. Van Horssen J, Schreibelt G, Bo L, et al. NAD(P)H: quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med. 2006 ; 41: 311-317
4. Smith KJ, Kapoor R, Hall SM, et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol. 2001 ; 49: 470-476
5. Qi X, Lewin AS, Sun L, et al. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem. 2006 ; 281: 31950-62
6. Besler HT, Comoglu S, Okcu Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci. 2002 ; 5: 215-220
7. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci. 2003 ; 6: 189-196
8. Ristori G, Brescianini S, Pino A, et al. Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity. Neurology. 2011 ; 76: 549-555
9. Ferretti G, Bacchetti T, Principi F, et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler. 2005 ; 11: 677-682
10. Koch M, Mostert J, Arutjunyan AV, et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol. 2007 ; 14: 529-533
11. Greco A, Minghetti L, Sette G, et al. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology. 1999 ; 53: 1876-1879
12. Greco A, Minghetti L, Puopolo M, et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci. 2004 ; 224: 23-27
13. Miller E, Mrowicka M, Saluk-Juszczak J, et al. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res. 2011 ; 36: 1012-6
14. Mattsson N, Haghighi S, Andersen O, et al. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett. 2007 ; 414: 233-236
15. De Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006 ; 27: 394-401
16. Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002 ; 59: 972-976
17. Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging. 2011 ;:
18. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005 ; 4: 341-348
19. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler. 2002 ; 8: 93-97
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
21. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997 ; 120: 2059-2069
22. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122: 871-82
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
24. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 ; 73: 1914-1922
25. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
26. Qin Y, Duquette P, Zhang Y, et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest. 2003 ; 83: 1081-1088
27. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003 ; 349: 139-145
28. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler. 2005 ; 11: 492-494
29. Tumani H, Lehmensiek V, Rau D, et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009 ; 452: 214-217
30. Comabella M, Montalban X, Kakalacheva K, et al. B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS. J Neuroimmunol. 2010 ; 223: 135-137
31. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One. 2010 ; 5: e11986
32. Ristori G, Brescianini S, Pino A, et al. Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity. Neurology. 2011 ; 76: 549-555
33. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005 ; 4: 281-288
34. Mufson EJ, Leurgans S. Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis. 2010 ; 7: 139-142
35. Irizarry MC, Yao Y, Hyman BT, et al. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis. 2007 ; 4: 403-405